Marshall Wace North America’s Accelerate Diagnostics AXDX Stock Holding History

Marshall Wace North America’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,626	Closed	-$135K	–	1451
2021 Q1	$135K	Sell	1,626 -1,822	-53%	-$185K	﹤0.01%	1432
2020 Q4	$261K	Hold	3,448	–	–	﹤0.01%	1190
2020 Q3	$368K	Sell	3,448 -1,818	-35%	-$252K	﹤0.01%	1031
2020 Q2	$799K	Buy	5,266 +4,030	+326%	+$397K	0.01%	818
2020 Q1	$103K	Buy	+1,236	New	+$174K	﹤0.01%	991
2019 Q4	–	Sell	-1,349	Closed	-$251K	–	1280
2019 Q3	$251K	Buy	+1,349	New	+$261K	﹤0.01%	922
2017 Q4	–	Sell	-13,975	Closed	-$3.07M	–	1366
2017 Q3	$3.07M	Buy	13,975 +9,481	+211%	+$2.33M	0.02%	682
2017 Q2	$1.21M	Buy	+4,494	New	+$1.22M	0.01%	880

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace North America's AXDX Position: Q2 2021 in Review

Marshall Wace North America sold out of Accelerate Diagnostics (AXDX) in Q2 2021, closing a stake of 1,626 shares — an estimated $135K sold.

Marshall Wace North America first reported a position in AXDX in Q2 2017 and held it in 8 quarters. The position peaked at $3.07M in Q3 2017. 95 funds tracked by Wall St. Rank hold AXDX as of Q2 2021.

Marshall Wace North America reported no remaining Accelerate Diagnostics position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 1,626 Accelerate Diagnostics shares in Q2 2021, an estimated $135K.
Marshall Wace North America first reported a position in Accelerate Diagnostics in Q2 2017 and held it in 8 quarters.
Marshall Wace North America's Accelerate Diagnostics position peaked at $3.07M in Q3 2017.
95 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.